Compare ARQQ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | FHTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.7M | 332.2M |
| IPO Year | N/A | 2020 |
| Metric | ARQQ | FHTX |
|---|---|---|
| Price | $13.85 | $4.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $60.00 | $11.50 |
| AVG Volume (30 Days) | ★ 180.4K | 126.7K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $381.13 | $14.62 |
| Revenue Next Year | $212.00 | $15.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $11.00 | $2.94 |
| 52 Week High | $62.00 | $6.95 |
| Indicator | ARQQ | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 34.93 |
| Support Level | N/A | $4.44 |
| Resistance Level | $17.81 | $5.85 |
| Average True Range (ATR) | 0.96 | 0.37 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 1.91 | 15.02 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.